Draig Therapeutics Raises $65 Million in Series B Funding
Draig Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for mental health and neurological disorders, announced it has raised $65 million in a Series B funding round. This round was led by Deep Track Capital and included participation from Janus Henderson Investors, Marshall Wace, British Business Bank, and Jefferson Life Sciences.
Leadership and Company Focus
The company is helmed by Ivana Magovcevic-Liebisch, who serves as President and CEO, and Simon Ward, the Founder and Chief Scientific & Development Officer. Draig Therapeutics is primarily working on its lead drug, DT-101, which is currently in Phase 2 clinical trials for major depressive disorder (MDD).
In a statement, Magovcevic-Liebisch emphasized the significance of the funding, noting, "Major depressive disorder remains one of the largest unmet needs in medicine. Our next-generation AMPA receptor modulator, DT-101, has shown encouraging safety, tolerability, and target engagement data. This new financing will enable us to accelerate the development of our pipeline."
Use of Funds
The newly acquired funds will be directed towards advancing Draig's mental health treatment pipeline. Specifically, the company plans to use the capital to accelerate the development of DT-101 and other promising candidates in its portfolio. The focus is on moving these treatments through clinical trials and eventually bringing them to market.
Investor Support and Market Impact
The funding round was oversubscribed, indicating strong investor confidence in Draig's approach and potential. Lead investor Deep Track Capital, along with other participating investors, expressed their support for the company's mission to address critical gaps in mental health treatment. The involvement of such reputed investors may also provide strategic insights and additional resources to bolster Draig's efforts.
This substantial investment reflects the growing interest in innovative treatments for mental health disorders, an area that continues to see significant demand and limited effective solutions. Draig Therapeutics is well-positioned to make impactful advancements in this space, potentially improving outcomes for patients suffering from conditions like MDD.
Conclusion
With this Series B funding, Draig Therapeutics is set to expedite its research and development activities, particularly focusing on advancing DT-101 through clinical trials. This progress marks a crucial step towards providing new therapeutic options for individuals with mental health disorders, aiming to enhance their quality of life.